AbbVie v. Teva: Teva Admits Infringement of Elagolix Patent, Injunction Issued
AbbVie filed suit against Teva in the District of Delaware in March 2023, asserting US Patent No. 11,542,239 against Teva’s ANDA 217650 for a generic elagolix sodium co-packaged product. Within 278 days, Teva admitted the patent was valid, enforceable, and infringed — and accepted a permanent injunction blocking any commercial launch for the life of the patent.
Teva concedes validity and infringement in ANDA dispute over Orilissa combo pack
AbbVie, Inc. filed this patent infringement action on March 30, 2023 in the United States District Court for the District of Delaware, asserting U.S. Patent No. 11,542,239 against Teva Pharmaceutical Industries, Ltd. The suit arose from Teva’s submission of Abbreviated New Drug Application No. 217650 to the FDA, seeking approval for a generic version of AbbVie’s co-packaged elagolix sodium, estradiol, and norethindrone acetate capsule product — the add-back therapy formulation used alongside Orilissa. The ‘239 Patent covers elagolix sodium compositions and related processes, sitting at the heart of AbbVie’s endometriosis franchise protection strategy.
The case closed on January 2, 2024 via a consent Stipulation and Order signed by both parties and entered by the court. Critically, Teva did not merely agree to dismiss — it formally admitted that the ‘239 Patent is valid, enforceable, and would be infringed by commercial sale of the ANDA 217650 products, and that the ANDA filing itself constituted an act of infringement under 35 U.S.C. § 271(e)(2)(A). The court issued a permanent injunction prohibiting Teva from manufacturing, using, selling, or importing the ANDA 217650 products for the remaining life of the patent, absent an AbbVie license. All remaining claims, counterclaims, and defenses were dismissed without prejudice.
A resolution in under nine months — with a full validity admission rather than a settlement that sidesteps the merits — is commercially significant. It suggests AbbVie held a strong patent position and Teva saw limited prospects for a successful invalidity or non-infringement challenge. The without-prejudice dismissal of remaining claims preserves the ability of either party to litigate future disputes over the ‘239 Patent in relation to products other than those covered by ANDA 217650. The underlying licensing terms, if any, remain undisclosed in the public record.
Filing to voluntary dismissal in 278 days
278 days from filing to stipulated order — resolved without trial
Stipulated Order: Teva admits infringement, permanent injunction entered
What a 35 U.S.C. § 271(e)(2)(A) admission means
Under the Hatch-Waxman framework, filing an ANDA referencing a patented drug is a statutory act of infringement under § 271(e)(2)(A) — even before any commercial sale occurs. Teva’s admission that its ANDA filing infringed the ‘239 Patent is a formal, on-the-record concession that goes beyond a litigation settlement. It forecloses any argument that the ANDA pathway was non-infringing, and provides AbbVie a documented precedent for future enforcement against related ANDAs.
Hatch-Waxman ANDA infringementWithout prejudice on remaining claims — what stays open
While the core infringement finding and injunction are final, remaining claims, counterclaims, and defenses were dismissed without prejudice. This means either party may raise them in a future action — but only regarding the ‘239 Patent and a product other than ANDA 217650’s subject matter. The Order explicitly preserves this right. AbbVie’s infringement win and the injunction itself are not affected and cannot be relitigated by Teva under this Order.
Without prejudice — future claims preservedPermanent injunction covers the full life of the ‘239 Patent
The court’s order permanently enjoins Teva — and its officers, agents, employees, and anyone acting in concert — from any commercial activity with ANDA 217650 products in the US market for the remaining life of US11542239. The only exit is an AbbVie license or other explicit authorisation. This is a stronger commercial outcome for AbbVie than a typical ANDA consent judgment that merely sets an entry date, as it provides no automatic pathway to market.
Permanent injunction — no launch date setBoth parties waived all rights to appeal this Order
The Stipulation and Order includes an express, mutual waiver of appeal rights. This is relatively uncommon in ANDA litigation and signals that both parties regarded the resolution as final and acceptable. For AbbVie, it locks in the infringement finding and injunction. For Teva, it suggests the commercial calculus — likely including undisclosed licensing discussions — made the admission preferable to the cost and uncertainty of continued litigation over a patent Teva’s counsel may have assessed as strong.
Appeal rights expressly waivedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Biopharmaceutical company — holder of US11542239B2 covering elagolix sodium compositionsSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer; filer of ANDA 217650 for generic elagolix sodiumSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily DiBenedetto | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Karen Elizabeth Keller | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Stipulation and Order is structured as both a consent judgment and a permanent injunction — an unusually strong outcome for a plaintiff in an ANDA dispute. By admitting infringement under § 271(e)(2)(A) and waiving appeal rights, Teva foreclosed any future challenge to the ‘239 Patent’s validity or enforceability in the context of ANDA 217650. The without-prejudice carve-out for other products preserves both parties’ flexibility in future disputes but does not dilute the finality of this ruling on the specific ANDA products at issue.
US11542239B2 — Elagolix Sodium Compositions and Processes
U.S. Patent No. 11,542,239 covers elagolix sodium compositions and related manufacturing processes. The application was filed July 23, 2019 (Application No. 16/519,443), and the patent relates to the formulation and preparation of elagolix sodium — the active ingredient in AbbVie’s Orilissa (elagolix) and the elagolix-containing add-back therapy Oriahnn. The claims at issue in this case specifically encompass the co-packaged combination product containing elagolix sodium, estradiol, and norethindrone acetate at the dosage strengths described in Teva’s ANDA 217650.
The ‘239 Patent represents a downstream formulation and process patent layered over AbbVie’s core elagolix compound IP. In pharmaceutical patent strategy, such secondary patents are critical to extending commercial exclusivity beyond the primary compound patent expiry. This case — in which a major generic manufacturer conceded the patent’s validity and enforceability without contest — suggests the ‘239 Patent’s claims are drafted with sufficient specificity to withstand ANDA-driven invalidity pressure. Any manufacturer developing generic elagolix combination products should treat US11542239 as a primary blocking patent requiring careful FTO assessment.
Should your team run an FTO against US11542239B2?
Any pharmaceutical company or generic manufacturer with a development programme targeting elagolix sodium formulations — including co-packaged combination capsule products — should conduct a freedom-to-operate analysis against US11542239 before filing an ANDA or NDA. Teva’s admission in this case demonstrates that the ‘239 Patent’s claims are broad enough to read on co-packaged elagolix sodium and add-back hormone formulations at commercially relevant dosage strengths. The injunction’s scope — covering manufacture, use, sale, offer for sale, and import — means US market exposure exists at every commercial stage.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope against your specific formulation or process, identify design-around opportunities, and monitor continuation applications that could extend AbbVie’s elagolix patent family. Given that the without-prejudice dismissal of remaining claims leaves open future ‘239 Patent litigation against different products, ongoing claim monitoring is particularly important for teams working in adjacent elagolix composition space.
Run a freedom-to-operate analysis on US11542239B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases in the pharma composition space
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the pharma ANDA patent enforcement landscape
A full validity admission and permanent injunction in under nine months sets a high bar for generic challengers targeting AbbVie’s elagolix franchise.
AbbVie’s ‘239 Patent withstood a direct Hatch-Waxman challenge without trial
Teva’s unconditional admission that US11542239 is valid and enforceable — without any invalidity counterclaim surviving to adjudication — suggests the patent’s claim scope is robust. Generic manufacturers and competitors developing elagolix-adjacent formulations should treat the ‘239 Patent as a high-risk obstacle requiring early FTO analysis before ANDA or NDA filing.
Permanent injunctions in ANDA cases are powerful deterrents — not just delay tactics
Unlike settlements that establish a future entry date, this Order contains no authorised launch date. Teva cannot enter the market without AbbVie’s express consent for the life of the patent. This outcome demonstrates that aggressive early enforcement, backed by strong patent claims, can achieve a full market exclusivity lock — not merely a postponement of generic competition.
AbbVie v Teva — key questions answered
The case resolved on January 2, 2024 via a consent Stipulation and Order. Teva admitted that US Patent No. 11,542,239 is valid, enforceable, and would be infringed by its ANDA 217650 products. The court issued a permanent injunction prohibiting Teva from commercialising those products in the US for the life of the patent. Remaining claims were dismissed without prejudice.
US11542239B2 covers elagolix sodium compositions and processes, filed July 2019 (Application No. 16/519,443). The patent is relevant to the co-packaged elagolix sodium, estradiol, and norethindrone acetate capsule products sold by AbbVie as part of its Oriahnn add-back therapy for endometriosis-associated pain management.
Teva’s ANDA 217650 sought FDA approval to market a generic version of AbbVie’s co-packaged elagolix sodium (eq. 300 mg base), estradiol (1 mg), and norethindrone acetate (0.5 mg) capsule combination product. AbbVie asserted that the ANDA filing constituted statutory infringement of US11542239 under 35 U.S.C. § 271(e)(2)(A), the Hatch-Waxman infringement provision triggered by ANDA submissions referencing a patented drug.
In this case, ‘without prejudice’ applies only to the remaining claims, counterclaims, and defenses beyond the admitted infringement finding. The core infringement ruling and permanent injunction are final. The without-prejudice dismissal means either party may raise those remaining claims in a future action — but only regarding the ‘239 Patent and products other than those described in ANDA 217650.
No. The Stipulation and Order includes an express mutual waiver by both AbbVie and Teva of any right to appeal or otherwise move for relief from the Order. This waiver makes the infringement admission and permanent injunction entirely final. Teva cannot challenge the ruling through appellate proceedings.
PatSnap Eureka searches patents and litigation data to answer instantly.